CN107405352A - 神经活性化合物及其使用方法 - Google Patents
神经活性化合物及其使用方法 Download PDFInfo
- Publication number
- CN107405352A CN107405352A CN201580063540.7A CN201580063540A CN107405352A CN 107405352 A CN107405352 A CN 107405352A CN 201580063540 A CN201580063540 A CN 201580063540A CN 107405352 A CN107405352 A CN 107405352A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC*1=C(C2)C2CC1 Chemical compound CC*1=C(C2)C2CC1 0.000 description 3
- MGMBLURUUOVGLU-BJYRPUORSA-N C[C@H](CC(C(C)(C)O)(F)F)[C@@H](CC1)[C@@](C)(CC[C@@]2([C@H](CCCC[C@@](C)(C3)O)C3=CC[C@H]22)[I]=N)[C@@]12N=C Chemical compound C[C@H](CC(C(C)(C)O)(F)F)[C@@H](CC1)[C@@](C)(CC[C@@]2([C@H](CCCC[C@@](C)(C3)O)C3=CC[C@H]22)[I]=N)[C@@]12N=C MGMBLURUUOVGLU-BJYRPUORSA-N 0.000 description 1
- ZCKNSKLMRTZMIB-VHFVPTDGSA-N C[C@H](CC([C@H](C)O)(F)F)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O Chemical compound C[C@H](CC([C@H](C)O)(F)F)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O ZCKNSKLMRTZMIB-VHFVPTDGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011059273.5A CN112121171A (zh) | 2014-10-07 | 2015-10-07 | 神经活性化合物及其使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 | |
| US62/060,932 | 2014-10-07 | ||
| PCT/US2015/054551 WO2016057713A1 (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011059273.5A Division CN112121171A (zh) | 2014-10-07 | 2015-10-07 | 神经活性化合物及其使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107405352A true CN107405352A (zh) | 2017-11-28 |
Family
ID=55653736
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580063540.7A Pending CN107405352A (zh) | 2014-10-07 | 2015-10-07 | 神经活性化合物及其使用方法 |
| CN202011059273.5A Pending CN112121171A (zh) | 2014-10-07 | 2015-10-07 | 神经活性化合物及其使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011059273.5A Pending CN112121171A (zh) | 2014-10-07 | 2015-10-07 | 神经活性化合物及其使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170304321A1 (enExample) |
| EP (1) | EP3204011A4 (enExample) |
| JP (3) | JP2017530982A (enExample) |
| KR (1) | KR20170065637A (enExample) |
| CN (2) | CN107405352A (enExample) |
| AU (2) | AU2015330906A1 (enExample) |
| BR (1) | BR112017007053A2 (enExample) |
| CA (1) | CA2963938C (enExample) |
| IL (2) | IL292465B2 (enExample) |
| MX (2) | MX388694B (enExample) |
| MY (1) | MY202135A (enExample) |
| PE (1) | PE20170907A1 (enExample) |
| PH (1) | PH12017500639A1 (enExample) |
| RU (1) | RU2764702C2 (enExample) |
| SG (2) | SG10202011773UA (enExample) |
| WO (1) | WO2016057713A1 (enExample) |
| ZA (1) | ZA201702545B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| SG11201507320QA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| IL294448A (en) | 2013-12-24 | 2022-09-01 | Univ Virginia Commonwealth | Uses of oxidized cholesterol sulfates |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| EP3319610A4 (en) * | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| HUE059768T2 (hu) | 2016-08-02 | 2022-12-28 | Univ Virginia Commonwealth | 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP3335730A1 (en) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Compounds for treating x-linked adrenoleukodystrophy |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160441A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) * | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| NZ589764A (en) * | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2011028794A2 (en) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| US20150119327A1 (en) * | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014025942A1 (en) * | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| EA031905B1 (ru) * | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| ES2970222T3 (es) * | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) * | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| EP3319610A4 (en) * | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
-
2015
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/en active Pending
- 2015-10-07 IL IL292465A patent/IL292465B2/en unknown
- 2015-10-07 CA CA2963938A patent/CA2963938C/en active Active
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/en not_active Ceased
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Ceased
- 2015-10-07 MX MX2017004684A patent/MX388694B/es unknown
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160441A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107405352A (zh) | 神经活性化合物及其使用方法 | |
| JP7602512B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| JP7602513B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| JP6530804B2 (ja) | 神経刺激性ステロイドおよびその使用方法 | |
| JP6628745B2 (ja) | オキシステロールおよびその使用方法 | |
| RU2850468C2 (ru) | Оксистеролы и способы их применения | |
| HK40051330B (en) | Oxysterols and methods of use thereof | |
| HK40051330A (en) | Oxysterols and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171128 |
|
| RJ01 | Rejection of invention patent application after publication |